ContraFect’s CF-301 to enter phase one clinical trials

By Leif Skodnick

1 Comment

The Yonkers biotechnology company announces it will begin clinical trials of a treatment for drug-resistant Staph infections.

This content is for Westfair Online members only. Please login to view this content. Become a member by Registering Here. If you would prefer to start with a 12 week free trial, Click Here.


About the author

Leif Skodnick
Leif Skodnick is a former reporter for Westfair Communications. He is a graduate of Columbia Journalism School, Mississippi College School of Law, and St. Lawrence University.

Related Articles